T-Cell Lymphoma

Type: Keyphrase
Name: T-Cell Lymphoma
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Destructive Ulcerated Lesions of the Hard Palate

A 34-year-old woman presented with a 3-month history of ulcerated plaques on the palate and gingiva. Physical examination revealed two ulcerated lesions with irregular margins on the hard palate (Panel A) and gingival mucosa (Panel B). The palatal bone ... [Published New England Journal of Medicine - Oct 23 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

'His love was in worship'

Kevin Karhoff loved music, and it showed in his everyday life.First Reformed Church lost its worship leader Saturday when Karhoff, 47, died after a battle with T-cell lymphoma.Karhoff came to Mitchell in 2010 with his wife, Kim, and their seven adopted ... [Published Mitchell Daily Republic - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Five questions for Aratana CEO Steven St. Peter

It's been a productive couple of weeks for Aratana Therapeutics ($PETX). On October 10, at the Annual Veterinary Cancer Society meeting in St. Louis, MO, investigators working with the company presented key data on two of its lymphoma drugs. Then, last ... [Published Fierce Biotech IT - Oct 20 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma.

Br J Dermatol.2014;171(4):891-4  (ISSN: 1365-2133)Guenova E; Schanz S; Hoetzenecker W; DeSimone JA; Mehra T; Voykov B; Urosevic-Maiwald M; Berneburg M; Dummer R; French LE; Kerl K; Kamarashev J; Fierlbeck G; Cozzio ABACKGROUND:Primary cutaneous γ/δ T-cell ... [Published British Journal of Dermatology - Oct 18 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Detection of the G17V RHOA Mutation in Angioimmunoblastic T-Cell Lymphoma and Related Lymphomas Using Quantitative Allele-Specific PCR

by Rie Nakamoto-Matsubara, Mamiko Sakata-Yanagimoto, Terukazu Enami, Kenichi Yoshida, Shintaro Yanagimoto, Yusuke Shiozawa, Tohru Nanmoku, Kaishi Satomi, Hideharu Muto, Naoshi Obara, Takayasu Kato, Naoki Kurita, Yasuhisa Yokoyama, Koji Izutsu, Yasunori ... [Published Plosone.org - Oct 13 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

ONLINE FIRST: International Consortium Probes New Risk Factors for the Many Lymphoma Subtypes Now Identified

BY KURT SAMSONAn international consortium of researchers has identified and quantified risk factors associated with 11 non-Hodgkin lymphoma (NHL) subtypes.Each year, more than half a million people worldwide are diagnosed with NHL, a diverse group of ... [Published Oncology Times - Oct 13 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Aratana Therapeutics Announces Presentation Of Clinical Data at Annual Veterinary Cancer Society Meeting

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its first appearance at the Annual Veterinary Cancer ... [Published Benzinga.com - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

UPDATE: Piper Jaffray Initiates Coverage On Aratana Therapeutics Inc On Approaching Catalysts

In a report published Tuesday, Piper Jaffray analyst Kevin K. Ellich initiated coverage on Aratana Therapeutics Inc (NASDAQ: PETX) with an Overweight rating and $17.00 price target.In the report, Piper Jaffray noted, “We are initiating coverage of Aratana ... [Published Benzinga.com - Oct 07 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Seattle Genetics announces encouraging data from Phase I lymphoma trial

Seattle Genetics, Inc., a biotechnology company, has announced the data which includes a two-year durability analysis from a Phase I clinical trial of ADCETRIS in combination with chemotherapy for the treatment of newly diagnosed peripheral T-cell lymphoma, ... [Published Individual.com - Sep 29 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 1 reports

Seattle Genetics' Adcetris Positive in Durability Analysis

Seattle Genetics, Inc. ( SGEN ) announced data from a two-year durability analysis of a phase I study on Adcetris (in combination with CHP chemotherapy) for the treatment of patients newly diagnosed with CD30-positive peripheral T-cell lymphoma (:PTCL) ... [Published Yahoo! Finance - Sep 25 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

BELEODAQ (belinostat) for Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

This slideshow reviews drug information for BELEODAQ® (belinostat), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL).Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 9: Clinical ... [Published Chemotherapy Advisor - Sep 26 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 5 reports

BioAlliance's lymphoma drug Beleodaq gets accelerated approval from FDA

France-based BioAlliance Pharma has received topotarget accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq to treat patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). ... [Published PBR - News - Jul 04 2014]

Quotes

...insight into the impact of patient characteristics on treatment outcomes over 7 years among adult patients receiving Cimzia ® for Crohn's disease. "We are encouraged by these results, which provide valuable insights about demographic and clinical characteristics, such as baseline serum albumin as well as disease behavior and location, which may affect treatment response."
"His love was in worship," Ulmer said. "He loved music. During the week he would sing in his office on occasion. He'd serenade everyone in the office. And he had a terrific laugh."
...The first, titled, "Treatment of Canine B-Cell Lymphoma with Chemotherapy and a Canine Anti-CD20 Monoclonal Antibody: A Prospective Double-Blind, Randomized, Placebo-Controlled Study" was presented by Dr. Gregory Ogilvie of the Angel Care Cancer Center, California Veterinary Specialists, Carlsbad, California...
...of anthracycline-based chemotherapy," said Jonathan Drachman, M D , Chief Medical Officer and Executive vice president, R&D at Seattle Genetics. "Maturing data from this Phase I trial in patients who have advanced or high-risk disease characteristics demonstrate durable progression-free survival and overall survival rates, supporting our belief that this novel ADCETRIS-containing regimen has the potential to redefine the treatment of frontline PTCL. This hypothesis is being tested in our ongoing Phase III clinical trial, called ECHELON-2."

More Content

All (49) | News (42) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lymphomas: current and future treatment options [Published Pharmaceutical Journal - 7 hours ago]
Destructive Ulcerated Lesions of the Hard Palate [Published New England Journal of Medicine - Oct 23 2014]
UCB-sponsored Data on Cimzia® (certolizumab peg... [Published U-T San Diego - Oct 22 2014]
'His love was in worship' [Published Mitchell Daily Republic - Oct 21 2014]
Five questions for Aratana CEO Steven St. Peter [Published Fierce Biotech IT - Oct 20 2014]
Systemic corticosteroids for subcutaneous panni... [Published British Journal of Dermatology - Oct 18 2014]
Chimerix's (CMRX) CEO Michelle Berrey Hosts R&D... [Published Seeking Alpha - Oct 16 2014]
MicroRNA-22 Induces Endothelial Progenitor Cell... [Published Sexual Development - Oct 14 2014]
Angioimmunoblastic T-Cell Lymphoma (AILT)/ Immu... [Published MyNewsDesk - Oct 14 2014]
Detection of the G17V RHOA Mutation in Angioimm... [Published Plosone.org - Oct 13 2014]
ONLINE FIRST: International Consortium Probes N... [Published Oncology Times - Oct 13 2014]
Aratana Therapeutics Announces Presentation Of ... [Published Benzinga.com - Oct 10 2014]
UPDATE: Piper Jaffray Initiates Coverage On Ara... [Published Benzinga.com - Oct 07 2014]
Incidence of Malignancies in Diagnosed Celiac P... [Published General Medicine eJournal - Oct 07 2014]
Severe Refractory Coeliac Disease with Response... [Published Sexual Development - Oct 06 2014]
Noxa in Rheumatic Diseases [Published General Medicine eJournal - Oct 01 2014]
CNS Lymphoma Market - Global Segment and Foreca... [Published MyNewsDesk - Sep 30 2014]
Pfizer And Kyowa Hakko Kirin To Collaborate On ... [Published CBS Detroit - Sep 30 2014]
Seattle Genetics announces encouraging data fro... [Published Individual.com - Sep 29 2014]
Man presents with unilateral intermediate uveitis [Published Orthopedics Today - Sep 27 2014]
BELEODAQ (belinostat) for Relapsed or Refractor... [Published Chemotherapy Advisor - Sep 26 2014]
Seattle Genetics' Adcetris Positive in Durabili... [Published Yahoo! Finance - Sep 25 2014]
Corporate Governance prize awarded by AGEFI: On... [Published Scottrade - Sep 25 2014]
ESMO Guideline for Mantle Cell Lymphoma [Published General Medicine eJournal - Sep 25 2014]
Seattle Genetics Highlights Updated Progression... [Published Business Wire Health News - Sep 24 2014]
Elk River teen siblings share cancer stories [Published Minneapolis Star Tribune - Sep 18 2014]
Eminem Publishers Sue N.Z. Party: Intellectual ... [Published Bloomberg - Sep 17 2014]
Takeda Pharmaceutical to headquarter global onc... [Published Boston Globe - Sep 16 2014]
What is the Cause? Erythematous Rash [Published MedPageToday.com - medical news plus CME for ph ... - Aug 04 2014]
ZIOPHARM Oncology and Solasia Pharma Announce G... [Published GlobeNewswire - Jul 31 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Seattle Genetics Highlights Updated Progression... [Published Business Wire Health News - Sep 24 2014]
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data to be presented at the 2014 European Society for Medical Oncology (ESMO) Congress being held September 26-30, 2014 in Madrid, Spain. ...
What is the Cause? Erythematous Rash [Published MedPageToday.com - medical news plus CME for ph ... - Aug 04 2014]
(MedPage Today) -- An elderly patient with known T-cell lymphoma and splenomegaly develops a well demarcated erythematous lesion on her upper arm. A biopsy of the lesion demonstrates a neutrophilic infiltrate. ...
Weekly Roundup 7.4.14 [Published Eye on FDA - Jul 04 2014]
Happy Independence Day for America.  This week also so Canada Day.  So while a week where work productivity may have dipped, enjoyment factors probably drove up – at least in North America.  The season is marked by hot, humid days and stormy nights, ...
BioAlliance's lymphoma drug Beleodaq gets accel... [Published PBR - News - Jul 04 2014]
France-based BioAlliance Pharma has received topotarget accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq to treat patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). ...
BioAlliance Pharma: FDA approval of Beleodaq™ (... [Published Business Wire Health News - Jul 03 2014]
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Topotarget ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.